Home Drug IndexClinical Monograph

Doxycycline Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Antibacterial

Subclass

Tetracycline antibiotic

Speciality

Infectious Diseases

Schedule (India)

Schedule H

Routes

Oral, Intravenous

Formulations

Form	Strengths
Capsules	100 mg
Tablets	100 mg
Dispersible tablets	100 mg
Tablets (extended-release)	40 mg (sub-antimicrobial dose for rosacea)
Injection (powder for reconstitution)	100 mg/vial

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Scrub Typhus / Rickettsial Infections

Parameter	Recommendation
Starting dose	100 mg twice daily
Titration	Not applicable
Usual maintenance dose	100 mg twice daily
Maximum dose	200 mg/day
Duration	7 days (extend to 14 days if severe or delayed response)
Clinical notes	First-line therapy per ICMR/NCDC guidelines; continue until afebrile for 48–72 hours; highly endemic in Himalayan foothills, NE India, South India

2. Cholera

Parameter	Recommendation
Starting dose	300 mg single dose OR 100 mg twice daily
Titration	Not applicable
Usual maintenance dose	100 mg twice daily if multi-dose regimen
Maximum dose	300 mg/day
Duration	Single dose or 3 days
Clinical notes	Adjunct to ORS; reduces stool output and vibrio shedding; per NCDC outbreak guidelines

3. Uncomplicated Genital Chlamydia Infection

Parameter	Recommendation
Starting dose	100 mg twice daily
Titration	Not applicable
Usual maintenance dose	100 mg twice daily
Maximum dose	200 mg/day
Duration	7 days
Clinical notes	First-line per NACO STI guidelines; treat partner simultaneously; test-of-cure not routinely needed

4. Non-Gonococcal Urethritis / Cervicitis

Parameter	Recommendation
Starting dose	100 mg twice daily
Titration	Not applicable
Usual maintenance dose	100 mg twice daily
Maximum dose	200 mg/day
Duration	7 days
Clinical notes	Covers Chlamydia and Mycoplasma genitalium; combine with ceftriaxone if gonorrhoea not excluded

5. Pelvic Inflammatory Disease (PID)

Parameter	Recommendation
Starting dose	100 mg twice daily
Titration	Not applicable
Usual maintenance dose	100 mg twice daily
Maximum dose	200 mg/day
Duration	14 days
Clinical notes	Use with ceftriaxone 250 mg IM single dose ± metronidazole 500 mg twice daily; per NACO syndromic management guidelines

6. Leptospirosis (Mild–Moderate)

Parameter	Recommendation
Starting dose	100 mg twice daily
Titration	Not applicable
Usual maintenance dose	100 mg twice daily
Maximum dose	200 mg/day
Duration	7 days
Clinical notes	Effective if started within first 4 days of illness; IV penicillin preferred for severe/icteric disease

7. Brucellosis

Parameter	Recommendation
Starting dose	100 mg twice daily
Titration	Not applicable
Usual maintenance dose	100 mg twice daily
Maximum dose	200 mg/day
Duration	6 weeks
Clinical notes	Always combine with streptomycin (first 2–3 weeks) OR rifampicin (full 6 weeks); monotherapy leads to high relapse

8. Malaria Chemoprophylaxis

Parameter	Recommendation
Starting dose	100 mg once daily
Titration	Not applicable
Usual maintenance dose	100 mg once daily
Maximum dose	100 mg/day
Duration	Start 1–2 days before travel; continue during stay + 4 weeks after leaving endemic area
Clinical notes	Use when mefloquine/atovaquone-proguanil contraindicated or unavailable; not for treatment of acute malaria as monotherapy

9. Severe Malaria (Adjunct Therapy)

Parameter	Recommendation
Starting dose	100 mg twice daily
Titration	Not applicable
Usual maintenance dose	100 mg twice daily
Maximum dose	200 mg/day
Duration	7 days
Clinical notes	Always combine with IV artesunate or quinine; never use as monotherapy; per NVBDCP guidelines

10. Acne Vulgaris (Moderate–Severe Inflammatory)

Parameter	Recommendation
Starting dose	100 mg once daily OR 50 mg twice daily
Titration	Not applicable
Usual maintenance dose	50–100 mg once daily
Maximum dose	100 mg/day
Duration	6–12 weeks (reassess; avoid prolonged use >3–4 months)
Clinical notes	Second-line after topical therapy fails; combine with topical retinoid and benzoyl peroxide; taper to sub-antimicrobial dose or stop once controlled

11. Rosacea (Papulopustular)

Parameter	Recommendation
Starting dose	40 mg once daily (modified-release) OR 50 mg once daily (immediate-release)
Titration	Not applicable
Usual maintenance dose	40–50 mg once daily
Maximum dose	100 mg/day (if 40 mg insufficient)
Duration	8–16 weeks
Clinical notes	Sub-antimicrobial dosing preferred to minimise resistance; combine with topical metronidazole or azelaic acid

12. Community-Acquired Pneumonia (Atypical Pathogens)

Parameter	Recommendation
Starting dose	100 mg twice daily
Titration	Not applicable
Usual maintenance dose	100 mg twice daily
Maximum dose	200 mg/day
Duration	7–14 days
Clinical notes	Covers Mycoplasma, Chlamydophila, Legionella; use as monotherapy only for mild atypical pneumonia; combine with beta-lactam for moderate–severe CAP

13. Q Fever (Coxiella burnetii)

Parameter	Recommendation
Starting dose	100 mg twice daily
Titration	Not applicable
Usual maintenance dose	100 mg twice daily
Maximum dose	200 mg/day
Duration	Acute: 14 days; Chronic (endocarditis): 18–24 months with hydroxychloroquine
Clinical notes	Chronic Q fever requires specialist management; add hydroxychloroquine to enhance intracellular killing

14. Plague (Yersinia pestis)

Parameter	Recommendation
Starting dose	100 mg twice daily OR 200 mg once daily
Titration	Not applicable
Usual maintenance dose	100 mg twice daily
Maximum dose	200 mg/day
Duration	10–14 days
Clinical notes	Alternative to streptomycin/gentamicin; per NCDC outbreak protocols; strict infection control required

15. Anthrax (Post-Exposure Prophylaxis & Cutaneous)

Parameter	Recommendation
Starting dose	100 mg twice daily
Titration	Not applicable
Usual maintenance dose	100 mg twice daily
Maximum dose	200 mg/day
Duration	PEP: 60 days; Cutaneous: 7–10 days
Clinical notes	Ciprofloxacin is alternative first-line; for inhalational/systemic anthrax, use IV doxycycline in multidrug regimen

16. Lymphogranuloma Venereum (LGV)

Parameter	Recommendation
Starting dose	100 mg twice daily
Titration	Not applicable
Usual maintenance dose	100 mg twice daily
Maximum dose	200 mg/day
Duration	21 days
Clinical notes	Per NACO guidelines; azithromycin is alternative; aspirate fluctuant buboes (do not incise)

17. Granuloma Inguinale (Donovanosis)

Parameter	Recommendation
Starting dose	100 mg twice daily
Titration	Not applicable
Usual maintenance dose	100 mg twice daily
Maximum dose	200 mg/day
Duration	Minimum 3 weeks; continue until complete epithelialisation
Clinical notes	Endemic in parts of India; azithromycin is alternative; prolonged treatment often required

18. Periodontitis (Adjunctive Therapy)

Parameter	Recommendation
Starting dose	20 mg twice daily (sub-antimicrobial dose)
Titration	Not applicable
Usual maintenance dose	20 mg twice daily
Maximum dose	40 mg/day
Duration	Up to 9 months
Clinical notes	Adjunct to scaling/root planing; anti-collagenase effect at sub-antimicrobial dose; does not promote resistance

Secondary Indications — Adults (Off-label)

MRSA skin/soft tissue infection	100 mg twice daily	5–10 days	RCT data; Indian dermatology practice	OFF-LABEL; alternative when TMP-SMX unavailable
Small intestinal bacterial overgrowth (SIBO)	100 mg twice daily	7–10 days	Limited RCT data	OFF-LABEL; Specialist only; when rifaximin unavailable
Early Lyme disease (if documented travel history)	100 mg twice daily	14–21 days	International guidelines; rare in India	OFF-LABEL; very rare in India; confirm exposure history
Ehrlichiosis / Anaplasmosis	100 mg twice daily	7–14 days	Case reports; travel-related	OFF-LABEL; empiric for tick-borne illness with travel history
Pleural effusion sclerotherapy	500 mg in 30–50 mL NS intrapleurally	Single instillation	RCTs; Indian pulmonology practice	OFF-LABEL; Specialist only; for recurrent malignant effusions
Bullous pemphigoid (steroid-sparing)	100–200 mg/day	Months	RCT evidence (BLISTER trial)	OFF-LABEL; Specialist only; with topical steroids
Chronic prostatitis (Category II/III)	100 mg twice daily	4–6 weeks	Urology practice	OFF-LABEL; when atypical organisms suspected

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

⚠️ Age Restriction

Generally avoided in children <8 years due to risk of permanent teeth staining and enamel hypoplasia
Exception: May be used in children <8 years for life-threatening infections (scrub typhus, Rocky Mountain spotted fever, anthrax, severe malaria) when benefits outweigh risks — specialist supervision mandatory
Recent evidence suggests short courses (≤21 days) may have minimal dental effects, but caution persists in Indian practice

Weight-Based Dosing (Children ≥8 years)

Weight Category	Loading Dose (Day 1)	Maintenance Dose	Maximum Daily Dose
<45 kg	4 mg/kg (divided q12h)	2–4 mg/kg/day (single or divided)	200 mg/day
≥45 kg	Adult dosing applies	100 mg once or twice daily	200 mg/day

Primary Paediatric Indications

1. Scrub Typhus / Rickettsial Disease

Parameter	Children ≥8 years	Children <8 years (life-threatening only)
Dose	2.2 mg/kg twice daily (max 100 mg/dose)	2.2 mg/kg twice daily (max 100 mg/dose)
Duration	7 days or until afebrile 48–72 hours	5–7 days (shortest effective course)
Notes	First-line per IAP/ICMR	Specialist only; benefits outweigh dental risk in severe disease

2. Malaria Chemoprophylaxis

Parameter	Recommendation
Minimum age	≥8 years
Dose	2 mg/kg once daily (max 100 mg)
Duration	1–2 days before travel through 4 weeks after
Notes	Alternative when atovaquone-proguanil unavailable

3. Severe Malaria (Adjunct)

Parameter	Recommendation
Age	≥8 years (or <8 years if benefits outweigh risks)
Dose	2.2 mg/kg twice daily (max 100 mg/dose)
Duration	7 days
Notes	Always combine with IV artesunate; never monotherapy

4. Cholera

Parameter	Recommendation
Age	≥8 years
Dose	2–4 mg/kg/day in single or divided doses
Duration	Single dose or 3 days
Notes	Adjunct to ORS; reduces disease duration

5. Anthrax (Post-Exposure Prophylaxis)

Parameter	Recommendation
Age	Any age (including <8 years due to severity)
Dose	2.2 mg/kg twice daily (max 100 mg/dose)
Duration	60 days
Notes	Life-saving indication overrides dental concerns

Secondary Paediatric Indications (Off-label)

Indication	Age	Dose	Duration	Notes
Mycoplasma pneumoniae pneumonia	≥8 years	2 mg/kg twice daily (max 100 mg/dose)	7–10 days	OFF-LABEL; when macrolide-resistant suspected
Acne vulgaris (moderate–severe)	≥12 years	50–100 mg once daily	6–12 weeks	OFF-LABEL; with topical therapy

Safety Monitoring in Paediatrics

Monitor for GI upset; administer with food if needed
Advise upright posture for 30 minutes post-dose
Sun protection during treatment
Dental surveillance if used in children <8 years
Document indication clearly when used off-label or in younger children

Renal Adjustments

No dose adjustment required for most patients.

Renal Function	Recommendation
eGFR >30 mL/min	No adjustment needed
eGFR 10–30 mL/min	Standard dose acceptable for short courses; avoid prolonged therapy
eGFR <10 mL/min	Use with caution; standard dose acceptable but monitor for accumulation
Haemodialysis	Not significantly removed; no supplemental dose required
Peritoneal dialysis	Not significantly removed; standard dosing
CRRT	Standard dosing; monitor clinically

Clinical Note: Unlike other tetracyclines, doxycycline is primarily excreted via GI tract (chelated in intestines), making it safer in renal impairment.

Hepatic adjustment

Contraindications

Known hypersensitivity to doxycycline, any tetracycline, or excipients
Pregnancy (second and third trimesters) — absolute contraindication
Children <8 years — relative contraindication (except life-threatening infections under specialist care)
Concurrent use with systemic retinoids (isotretinoin, acitretin) — risk of benign intracranial hypertension
Myasthenia gravis — may exacerbate weakness (use only if no alternative and with close monitoring)

Cautions

Oesophageal injury: Administer with adequate water; maintain upright posture for 30 minutes; avoid bedtime dosing
Photosensitivity: Advise sun avoidance and protective measures
First trimester pregnancy: Use only if no safer alternative and benefit outweighs risk
Systemic lupus erythematosus: May exacerbate; use with caution
History of oral/oesophageal surgery or strictures
Concurrent hepatotoxic drugs
Prolonged use: Risk of superinfection (Candida, Clostridioides difficile)
Intracranial hypertension history

Pregnancy

Parameter	Details
Risk Category	Contraindicated in 2nd and 3rd trimesters
Risk Summary	Crosses placenta; causes permanent teeth discoloration (yellow-brown), enamel hypoplasia, and inhibition of bone growth in fetus
First Trimester	Limited data; may be used if benefits clearly outweigh risks and no alternative exists
Preferred Alternatives	Azithromycin (for chlamydia, atypicals), Amoxicillin (for respiratory infections), Penicillin (for syphilis), Ceftriaxone (for gonorrhoea)
When May Be Used	Life-threatening maternal infection with no suitable alternative (e.g., rickettsial disease) — specialist decision
Monitoring	If inadvertent exposure, counsel regarding risks; no specific fetal monitoring indicated

Lactation

Parameter	Details
Compatibility	Generally compatible for short courses
Milk Levels	Low; minimal excretion into breast milk
Infant Absorption	Poorly absorbed by infant due to chelation with milk calcium
Preferred Alternatives	Azithromycin (if appropriate for indication)
Infant Monitoring	Observe for oral candidiasis, loose stools; theoretical dental staining risk with prolonged maternal use is very low
Recommendation	Short courses (≤3 weeks) acceptable during breastfeeding; avoid prolonged therapy if possible

Elderly

Parameter	Recommendation
Starting Dose	Standard adult dosing (100 mg once or twice daily)
Titration	Not applicable
Special Considerations	Higher risk of oesophageal ulceration — ensure adequate hydration and upright posture; monitor for pill oesophagitis symptoms (dysphagia, odynophagia, retrosternal pain)
Renal Function	No dose adjustment typically needed
Drug Interactions	Review concurrent medications (antacids, iron, calcium supplements, anticoagulants)
Adverse Effects	Monitor for Clostridioides difficile infection; may be more susceptible

Major drug interactions

Interacting Drug	Effect	Mechanism	Recommendation
Isotretinoin / Acitretin	Risk of benign intracranial hypertension (pseudotumour cerebri)	Additive effect on intracranial pressure	AVOID combination
Methotrexate	Increased methotrexate toxicity	Decreased renal clearance; displaced protein binding	Avoid or use with extreme caution; monitor closely
Warfarin / Acenocoumarol	Enhanced anticoagulant effect; increased bleeding risk	Altered gut flora reducing vitamin K synthesis; possible CYP inhibition	Monitor INR closely; may need warfarin dose reduction
Ciclosporin	Increased ciclosporin levels	Unknown mechanism	Monitor ciclosporin levels
Antacids (Al/Mg/Ca-containing)	Markedly reduced doxycycline absorption	Chelation in GI tract	Separate by at least 2–3 hours
Oral iron preparations	Reduced absorption of both drugs	Mutual chelation	Separate by at least 2–3 hours
Calcium supplements / Dairy	Reduced doxycycline absorption	Chelation	Separate by 2 hours; or take doxycycline with low-calcium meal
Sucralfate	Reduced doxycycline absorption	Physical binding	Separate by at least 2 hours
Quinapril	Reduced quinapril absorption	Contains magnesium carbonate excipient	Separate administration

Moderate drug interactions

Interacting Drug	Effect	Recommendation
Rifampicin	Reduced doxycycline levels (half-life reduced by ~50%)	May need doxycycline 100 mg twice daily instead of once daily; monitor clinical response
Phenytoin / Carbamazepine / Phenobarbital	Reduced doxycycline efficacy	Enzyme induction; consider higher doxycycline dose or twice daily dosing
Oral contraceptives	Theoretical reduced efficacy (controversial)	Limited evidence; advise additional contraception during antibiotic course and 7 days after (as per standard practice)
Theophylline	Possible increased GI adverse effects	Monitor for nausea, vomiting
Digoxin	Possible increased digoxin levels (in ~10% patients)	Monitor digoxin levels if signs of toxicity
Penicillins	Possible antagonism (bacteriostatic vs bactericidal)	Clinical significance uncertain; avoid in severe infections like endocarditis/meningitis if possible
Lithium	Possible increased lithium levels	Monitor lithium levels
Kaolin-pectin antidiarrhoeals	Reduced doxycycline absorption	Separate by 2 hours

Common Adverse effects

Nausea, vomiting
Epigastric discomfort, dyspepsia
Diarrhoea
Photosensitivity (phototoxic dermatitis)
Oesophageal irritation / ulceration
Vaginal candidiasis
Oral candidiasis (thrush)
Headache
Skin rash (non-serious)

Serious Adverse effects

Adverse Effect	Clinical Notes
Benign intracranial hypertension (pseudotumour cerebri)	Headache, visual disturbances, papilloedema; discontinue immediately
Stevens-Johnson syndrome / Toxic epidermal necrolysis	Rare; discontinue immediately; hospitalisation required
Drug-induced hepatotoxicity	Monitor LFTs; discontinue if significant elevation
Clostridioides difficile colitis	May occur during or weeks after therapy; discontinue and treat appropriately
Severe photosensitivity / phototoxic bullous eruption	Discontinue; supportive care
Oesophageal ulceration / stricture	Odynophagia, retrosternal pain; prevention is key
Exacerbation of myasthenia gravis	Worsening weakness; avoid in known MG
Hypersensitivity reactions / Anaphylaxis	Rare; standard management
Permanent teeth discoloration	In children <8 years; enamel hypoplasia

Monitoring requirements

Timing	Parameters
Baseline	LFTs if prolonged course planned (>2–3 weeks); renal function (for drug interaction assessment, not dose adjustment)
During Therapy	Clinical response; signs of oesophageal irritation; skin for photosensitivity; signs of superinfection
Long-term Use (>3 months)	LFTs every 2–3 months; monitor for C. difficile symptoms; periodic dental check in younger patients
If on Anticoagulants	INR within 3–5 days of starting and after stopping
Symptoms of Intracranial Hypertension	Immediate ophthalmological evaluation if headache, visual changes, papilloedema

Brands in India

Doxt	Dr. Reddy's	Capsules 100 mg
Doxycee	Cipla	Capsules 100 mg
Doxy-1	Micro Labs	Capsules/Tablets 100 mg
Microdox	Micro Labs	Capsules 100 mg
Doxrid	Ridley Life Sciences	Capsules 100 mg
Biodoxi	Biochem	Capsules 100 mg
Tetradox	Alkem	Capsules 100 mg
Doxybond	Mankind	Capsules 100 mg
Doxiford	Intas	Capsules 100 mg

Fixed-Dose Combinations (Common)

Brand Name	Combination	Use
Doxt-SL	Doxycycline + Lactobacillus	GI protection

Price range (INR)

Formulation	Approximate Price	Notes
Capsules 100 mg (strip of 10)	₹50–120	Wide brand variation
Tablets 100 mg (strip of 10)	₹40–100
Injection 100 mg vial	₹80–200	Limited use

NLEM Status: Doxycycline is included in National List of Essential Medicines (NLEM) 2022
DPCO Price Control: Subject to price ceiling under DPCO
Government Supply: Available in public health facilities under national programmes (NVBDCP, RNTCP TB-HIV)

Clinical pearls

First-line for scrub typhus — Critical to recognise rickettsial illness in endemic areas (Himalayan belt, NE India, South India); do not wait for serology to initiate treatment in clinically suspected cases
Take upright with full glass of water — Most common preventable ADR is oesophageal ulceration; advise patients to remain upright 30 minutes post-dose and avoid bedtime administration
Food minimally affects absorption — Unlike other tetracyclines, doxycycline can be given with food to reduce GI upset (except high-calcium meals/dairy)
Photosensitivity counselling — Less photosensitive than other tetracyclines but still significant; advise sunscreen SPF 30+, protective clothing, avoidance of prolonged sun exposure
Preferred tetracycline in renal impairment — Primary excretion via intestinal chelation, not kidneys; safe to use without dose adjustment in CKD
STI syndromic management — For urethral/cervical discharge, combine with ceftriaxone 250 mg IM (single dose) to cover both gonorrhoea and chlamydia per NACO guidelines
Acne duration — Limit oral antibiotic courses to 6–12 weeks; always combine with topical retinoid and benzoyl peroxide to reduce resistance emergence

Version

RxIndia v0.1 — 27 Jan 2025

Reference

- CDSCO approved prescribing information for Doxycycline
- Indian Pharmacopoeia 2022
- NLEM India 2022
- NCDC Treatment Modules — Scrub Typhus, Cholera, Plague
- NVBDCP Guidelines — Malaria Chemoprophylaxis and Treatment
- NACO STI/RTI Technical Guidelines 2014 (updated)
- ICMR — Rickettsial Disease Guidelines
- API Textbook of Medicine (11th Edition) — Rickettsial infections, Leptospirosis, Brucellosis
- IAP Textbook of Pediatrics — Antimicrobial dosing
- Goodman & Gilman's The Pharmacological Basis of Therapeutics (14th Edition)
- Harrison's Principles of Internal Medicine (21st Edition)
- BLISTER trial (off-label bullous pemphigoid reference)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...